Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD
Published: Wednesday, Oct 04, 2017



Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 
SELECTED
LANGUAGE


Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication
x